462 reports of this reaction
1.5% of all BENDAMUSTINE HCL reports
#14 most reported adverse reaction
SEPSIS is the #14 most commonly reported adverse reaction for BENDAMUSTINE HCL, manufactured by Meitheal Pharmaceuticals Inc.. There are 462 FDA adverse event reports linking BENDAMUSTINE HCL to SEPSIS. This represents approximately 1.5% of all 30,914 adverse event reports for this drug.
Patients taking BENDAMUSTINE HCL who experience sepsis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
SEPSIS is a less commonly reported adverse event for BENDAMUSTINE HCL, but still significant enough to appear in the safety profile.
In addition to sepsis, the following adverse reactions have been reported for BENDAMUSTINE HCL:
The following drugs have also been linked to sepsis in FDA adverse event reports:
SEPSIS has been reported as an adverse event in 462 FDA reports for BENDAMUSTINE HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
SEPSIS accounts for approximately 1.5% of all adverse event reports for BENDAMUSTINE HCL, making it a notable side effect.
If you experience sepsis while taking BENDAMUSTINE HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.